Study of PRO 140 for Prophylaxis of Acute GVHD in Patients Undergoing RIC Allogenic Stem-Cell Transplantaton
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This is an Open-Label, Single-Arm, Phase II Multicenter Study of the Safety and Efficacy of
PRO 140 for Prophylaxis of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing
Reduced Intensity Conditioning (RIC) Allogeneic Stem-Cell Transplantation.
Phase:
Phase 2
Details
Lead Sponsor:
CytoDyn, Inc.
Collaborator:
Amarex Clinical Research
Treatments:
HIV Antibodies Leronlimab PRO-140 monoclonal antibody